Mihalj Seke

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

P. Kellokumpu-Lehtinen, M. Taalikka, C. Thellenberg-Karlsson, 2012, Prostate Cancer and Prostatic Diseases.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

N. James, A. Cross, Chris Parker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

J. Mohler, P. Kellokumpu-Lehtinen, M. Taalikka, 2012, Prostate Cancer and Prostatic Diseases.